• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Myriad Genetics Inc News

    18,18 $ +1,11% +0,20 $
    In : 17,002 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 897518
    ISIN: US62855J1043
    US-Symbol: MYGN
    Typ: Aktie

    Myriad Genetics Inc News

    28.09.23 - PR Newswire
    BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
    BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD PR Newswire
    02.03.23 - PR Newswire
    Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
    Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States PR Newswire
    31.08.22 - GlobeNewswire
    New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
    Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. ...
    31.08.22 - GlobeNewswire
    Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen
    Myriad Genetics’ EndoPredict-​Test identifiziert präzise prämenopausale Frauen mit ER+, HER2-Brustkrebs, die eine adjuvante Chemotherapie vermeiden können SALT LAKE CITY, ...
    16.08.22 - GlobeNewswire
    Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
    Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, France Latest expansions represent Myriad’s commitment to growing international lab partner ...
    16.08.22 - GlobeNewswire
    Myriad Genetics kooperiert mit dem Institut für Hämopathologie Hamburg und dem Centre Georges-Francois LeClerc, um den Zugang zu Gentests in Europa zu erweitern
    Zusammenarbeit bringt MyChoice CDx Plus Tests nach Hamburg, Deutschland und Dijon, Frankreich Jüngste Erweiterungen zeigen untermauern Myriad’s Verpflichtung gegenüber ...
    07.09.21 - PR Newswire
    Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
    Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations PR Newswire
    27.05.21 - PR Newswire
    IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety
    IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety PR Newswire
    18.01.21 - PR Newswire
    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
    30.11.20 - PR Newswire
    IPM Launches Innovative Program for Rheumatoid Arthritis
    IPM Launches Innovative Program for Rheumatoid Arthritis PR Newswire
    19.10.20 - GlobeNewswire
    Gemeinsamer Bundesausschuss (G-BA) fasst Beschluss zur Erstattung der Kosten des Brustkrebs-Prognosetests EndoPredict® durch die gesetzlichen Krankenkassen
    NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN
    16.10.20 - GlobeNewswire
    German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
    /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
    11.05.20 - PR Newswire
    Thinking about buying stock in Aurora Cannabis, Cytokinetics, Quotient, Myriad Genetics, or Avaya Holdings?
    Thinking about buying stock in Aurora Cannabis, Cytokinetics, Quotient, Myriad Genetics, or Avaya Holdings? PR Newswire
    23.11.19 - PR Newswire
    DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
    DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact ...
    18.11.19 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN
    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - ...
    05.11.19 - sharedeals.de
    Myriad Genetics: Ein wahrhaft hässliches Quartal!
    Zu den größten Verlierern am US-​Aktienmarkt zählt heute die Aktie des Biotechunternehmens Myriad Genetics (WKN: 897518). Grund hierfür sind die heute vorgelegten ...
    05.11.19 - Finanztrends
    Myriad Genetics: Ein wahrhaft hässliches Quartal!
    Zu den größten Verlierern am US-​Aktienmarkt zählt heute die Aktie des Biotechunternehmens Myriad Genetics (WKN: 897518). Grund hierfür sind die heute vorgelegten ...
    01.10.19 - PR Newswire
    MYGN CLASS ACTION DEADLINE: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Myriad Genetics
    MYGN CLASS ACTION DEADLINE: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Myriad Genetics PR Newswire
    30.09.19 - PR Newswire
    MYGN Loss Alert: Hagens Berman Notifies Investors in Myriad Genetics (MYGN) of Securities Fraud Lawsuit
    MYGN Loss Alert: Hagens Berman Notifies Investors in Myriad Genetics (MYGN) of Securities Fraud Lawsuit Class-​action law firm urges MYGN investors who have suffered losses ...
    30.09.19 - PR Newswire
    ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYGN
    ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc.; Encourages Investors with Losses in Excess of ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »